Drug Research

METiS TechBio has announced a strategic collaboration with Eli Lilly and Company to research and develop next-generation lipid nanoparticle (LNP)-based delivery solutions, leveraging METiS's proprietary AI-driven platform to enable precise, tissue-specific delivery of therapeutic modalities. Under the terms of the...

AstraZeneca has inked a billion-dollar AI drug discovery partnership and licensing deal with insitro to identify novel targets and therapies for a range of cardiometabolic diseases. Through this strategic agreement, the organizations will work in tandem to create drugs...

The pharmaceutical sector is increasingly turning to large-scale datasets to understand how medications perform beyond the controlled environment of clinical trials. While traditional research provides a foundation for drug approval, the actual impact of a therapy can only be...

The pharmaceutical industry is undergoing a fundamental shift in how it approaches patient diversity within clinical research. For decades, clinical trials often under-represented women, leading to gaps in knowledge regarding drug safety and efficacy for a significant portion of...

The pharmaceutical sector is witnessing a renewed focus on the complex biological changes associated with the transition into menopause. Central to this evolution is the depth of hormonal pathway research, which provides the foundation for developing more effective and...

Cardiovascular disease remains a leading cause of mortality among women, yet the mechanisms of disease progression often differ significantly from those observed in men. For many years, the pharmaceutical industry relied on generalized markers of heart health, which occasionally...

Autoimmune diseases affect women at a disproportionately high rate, with nearly 80 percent of all patients being female. Despite this staggering statistic, the underlying biological reasons for this disparity are only recently being understood with the necessary scientific depth....